- Home
- RILYP vs CGEN Comparison
RILYP vs CGEN Comparison
Compare RILYP & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILYP | CGEN |
|---|---|---|
| Founded | 1973 | 1993 |
| Country | United States | Israel |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 148.7M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | RILYP | CGEN |
|---|---|---|
| Price | $11.24 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.2K | ★ 319.5K |
| Earning Date | 01-01-0001 | 03-02-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $854,383,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $112.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $1.13 |
| 52 Week High | $14.50 | $2.38 |
Technical Indicators
Market Signals| Indicator | RILYP | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 49.24 |
| Support Level | $8.56 | $1.47 |
| Resistance Level | $14.50 | $2.35 |
| Average True Range (ATR) | 0.95 | 0.10 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 88.54 | 8.82 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.